Live Breaking News & Updates on Er Positive Breast Cancer

Stay updated with breaking news from Er positive breast cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CHMP Recommends Capivasertib/Fulvestrant for Pretreated ER+/HER2– Advanced Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

The EMA’s CHMP recommended capivasertib/fulvestrant for ER-positive, HER2-negative advanced breast cancer harboring PIK3CA, AKT1, or PTEN alterations. ....

Israel General , Comunidad Autonoma De Cataluna , Mafalda Oliveira , Department Of Medical Oncology At Vall , Hebron University Hospital , Hebron Institute Of Oncology Breast Cancer Group , European Medicines Agency , Medicinal Products , Human Use , Medical Oncology , Hebron Institute , Breast Cancer Group , Er Positive Breast Cancer , Pik3ca Alterations , Akt1 Alterations , Pten Alterations ,

SABR to Oligoprogressive Lesions Delays Change in Systemic Therapy in ER+ Advanced Breast Cancer

Administration of stereotactic ablative body radiotherapy to oligoprogressive lesions delayed a change in systemic therapy in patients with estrogen receptor–positive/HER2-negative breast cancer enrolled to the prospective phase 2 AVATAR trial.
....

Palbociclib Ibrance , Steven David , Peter Maccallum Cancer Centre , Breast Cancer , Stereotactic Ablative Body Radiotherapy , Oligoprogressive Lesions , Er Positive Breast Cancer , Avatar Trial , Astro Annual Meeting ,

NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast Cancer

The National Comprehensive Cancer Network Guidelines now recommend the use of 18F-Fluorestradiol positron emission tomography in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor–positive breast cancer. ....

United States , University Of Washington , Hannahm Linden , Mark Hibberd , David Mankoff , Ge Healthcare , National Comprehensive Cancer Network , Society Of Nuclear Medicine , Fred Hutchinson Cancer Center , University Of Pennsylvania , Use Criteria , Nuclear Medicine , Molecular Imaging , Pharmaceutical Diagnostics , Practice Guidelines , Zionexa United States , 18f Fluorestradiol , 18f Fes , Estrogen Receptor Positive Breast Cancer , Breast Cancer , Er Positive Breast Cancer ,